The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
A new hypoxic cell radiosensitizer, Ro 03-8799, has been administered i.v. to 2 normal and 6 patient volunteers. Generally in non-necrotic tumours the concentrations obtained were 3 times greater than in plasma sampled at the same time. These observations added to the reports concerning toxicology in monkeys and rats and radiosensitizing efficiency in the laboratory, suggest that Ro 03-8799 may prove to be much more effective sensitizer than misonidazole in man.
D000328:Adult; D000368:Aged; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D009336:Necrosis; D009369:Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D009593:Nitroimidazoles / Q000097:blood / Q000378:metabolism*; D011838:Radiation-Sensitizing Agents / Q000097:blood / Q000378:metabolism*
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; C033815:pimonidazole